0001493152-24-024600.txt : 20240620 0001493152-24-024600.hdr.sgml : 20240620 20240620205604 ACCESSION NUMBER: 0001493152-24-024600 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240617 FILED AS OF DATE: 20240620 DATE AS OF CHANGE: 20240620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Minev Boris Radoslavov CENTRAL INDEX KEY: 0001990402 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40789 FILM NUMBER: 241058189 MAIL ADDRESS: STREET 1: 4475 EXECUTIVE DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Calidi Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001855485 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 862967193 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4475 EXECUTIVE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-794-9600 MAIL ADDRESS: STREET 1: 4475 EXECUTIVE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: First Light Acquisition Group, Inc. DATE OF NAME CHANGE: 20210406 4 1 ownership.xml X0508 4 2024-06-17 0 0001855485 Calidi Biotherapeutics, Inc. CLDI 0001990402 Minev Boris Radoslavov C/O CALIDI BIOTHERAPEUTICS, INC. 4475 EXECUTIVE DRIVE, SUITE 200 SAN DIEGO, CA 92121 0 1 0 0 Interim Chief Medical Officer 0 Stock Options (right to buy) 0.195 2024-06-17 4 A 0 31360 A 2034-06-17 Common stock 31360 31360 D Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on June 17, 2024 (the "Grant Date"), the Reporting Person was granted 31,360 incentive stock options (the "Options") at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 9/13/2023. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. Exhibit 24 - Power of Attorney /s/ Andrew Jackson, Attorney-in-fact 2024-06-20 EX-24 2 ex24.htm

 

Exhibit 24

 

LIMITED POWER OF ATTORNEY

 

Know all by these presents, that the undersigned hereby constitutes and appoints each of Allan Camaisa, or Wendy Pizarro, or Andrew Jackson, in their capacity as executive officers, and Michael Cava, in his capacity as corporate counsel, of Calidi Biotherapeutics, Inc., each of them acting singly and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

 

(1) Prepare and execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer of Calidi Biotherapeutics, Inc., a Delaware corporation (the “Company”), Forms 3, 4 and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules thereunder;
   
(2) Do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the “SEC”), including without limitation the filing of any other documents necessary or appropriate to enable the undersigned to file the Forms 3, 4 and 5 electronically with the SEC; and
   
(3) Take any other action in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by or for, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever required, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney and the rights and powers herein granted.

 

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request and on the behalf of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with, or any liability for the failure to comply with, any provision of Section 16 of the Exchange Act.

 

This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

 

IN WITNESS WHEREOF, the undersigned has executed this Limited Power of Attorney as of this 25th day of January, 2024.

 

   
    SIGNATURE
     
    Boris Minev
    PRINTED NAME

 

 

 

GRAPHIC 3 ex24_001.jpg begin 644 ex24_001.jpg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end